Nicotine nanovaccines and uses thereof
Provided herein are nicotine polymer-stabilized nanoparticles, formulations thereof, and vaccines. Also provided herein are methods of treating and/or preventing nicotine addiction in a subject in need thereof.
1. A nanoparticle comprising:
a polymer core;
a lipid shell, wherein the lipid shell comprises a lipid bilayer comprising dioleoyl trimethylammonium propane (DOTAP) or a derivative thereof, DSPE (1,2-Distearoylphosphatidylethanolamine)-PEG (polyethylene glycol)-maleimide, and cholesterol, wherein the lipid shell encapsulates the polymer core;
a first stimulating molecule, wherein the first stimulating molecule is attached to the outer surface of the lipid shell;
a first nicotine-hapten antigen, wherein the first nicotine-hapten antigen is attached to the first stimulating molecule;
a second nicotine-hapten antigen, wherein the second nicotine-hapten antigen is attached to the outer surface of the lipid shell and wherein the second nicotine-hapten antigen is not attached to the first stimulating molecule; and
optionally, a second stimulating molecule, wherein the second stimulating molecule is attached to a polymer of the polymer core, encapsulated in a polymer of the polymer core, encapsulated in the lipid shell, embedded in the lipid bilayer, attached to the inner surface of the lipid shell, attached to the outer surface of the lipid shell, or any combination thereof.
2. The nanoparticle of claim 1 , wherein the polymer core comprises poly(lactic-co-glycolic acid).
3. The nanoparticle of claim 1 , wherein
the first stimulating molecule, the second stimulating molecule, or both are each independently selected from the group consisting of: keyhole limpet hemocyanin (KLH) multimer, KLH subunit, tetanus toxoid (TT), cross-reacting material 197 (CRM 197 ), bovine serum albumin (BSA), human papillomavirus (HPV) proteins, recombinant P. aeruginosa exoprotein A, recombinant cholera toxin B, outer protein capsid of bacteriophage Qb, a peptide, and any combination thereof.
4. The nanoparticle of claim 1 , wherein the first stimulating molecule, the second stimulating molecule, or both are each selected from the group consisting of: a toll-like receptor agonist, a dendritic cell surface molecule agonist, a NOD-like receptor agonist, antigen presenting cell agonist, and any combination. thereof.
5. The nanoparticle of claim 4 , wherein the toll-like receptor agonist is selected from a CpG oligodeoxynucleotide, a bacterial lipopolysaccharide, a VSV-G protein, HMGB-1, a TLR-1 agonist, a TLR-2 agonist, a TLR-3 agonist, a TLR-4 agonist, a TLR-5 agonist, a TLR-6 agonist, a TLR-7 agonist, a TLR-8 agonist, a TLR-9 agonist, a TLR-10 agonist, a urate crystal, monophosphoryl lipid A (MPLA), and any combination thereof.
6. The nanoparticle of claim 1 , wherein the total density of the first nicotine-hapten and the second nicotine-hapten ranges from about 52 to about 115 nicotine-hapten molecules per nanoparticle.
7. The nanoparticle of claim 1 , wherein the diameter of the nanoparticle ranges from about 1 nm to 999 nm.
8. A vaccine formulation comprising:
a nanoparticle of claim 1 ;
and
a pharmaceutically acceptable carrier.
9. The vaccine formulation of claim 8 , wherein the first stimulating molecule, the second stimulating molecule, or both are each independently selected from the group consisting of: keyhole limpet hemocyanin (KLH) multimer, KLH subunit, tetanus toxoid (TT), cross-reacting material 197 (CRM 197 ), bovine serum albumin (BSA), human papillomavirus (HPV) proteins, recombinant P. aeruginosa exoprotein A, recombinant cholera toxin B, outer protein capsid of bacteriophage Qb, a peptide, and any combination thereof.
10. The vaccine formulation of claim 8 , wherein the polymer core comprises poly(lactic-co-glycolic acid).
11. The vaccine formulation of claim 8 , wherein the first stimulating molecule, the second stimulating molecule, or both are each selected from the group consisting of: a toll-like receptor agonist, a dendritic cell surface molecule agonist, a NOD-like receptor agonist, antigen presenting cell agonist, and any combination thereof.
12. The vaccine formulation of claim 11 , wherein the toll-like receptor agonist is selected from a CpG oligodeoxynucleotide, a bacterial lipopolysaccharide, a VSV-G protein, HMGB-1, a TLR-1 agonist, a TLR-2 agonist, a TLR-3 agonist, a TLR-4 agonist, a TLR-5 agonist, a TLR-6 agonist, a TLR-7 agonist, a TLR-8 agonist, a TLR-9 agonist, a TLR-10 agonist, a urate crystal, monophosphoryl lipid A (MPLA), and any combination thereof.
13. The vaccine formulation of claim 8 , wherein the total density of the first nicotine-hapten and the second nicotine-hapten ranges from about 52 to about 115 nicotine-hapten molecules per nanoparticle.
14. The vaccine formulation of claim 8 , wherein the diameter of the nanoparticle ranges from about 1 nm to 999 nm.
15. The vaccine formulation of claim 8 , wherein the vaccine formulation does not contain Alum.
16. A method of treating nicotine addiction or a symptom thereof in a subject in need thereof, the method comprising:
administering a nanoparticle according to claim 1 ,
to the subject in need thereof.
17. The method of claim 16 , wherein the polymer core comprises poly(lactic-co-glycolic acid).
18. The method of claim 16 , wherein the first stimulating molecule, the second stimulating molecule, or both are each independently selected from the group consisting of: keyhole limpet hemocyanin (KLH) multimer, KLH subunit, tetanus toxoid (TT), cross-reacting material 197 (CRM 197 ), bovine serum albumin (BSA), human papillomavirus (HPV) proteins, recombinant P. aeruginosa exoprotein A, recombinant cholera toxin B, outer protein capsid of bacteriophage Qb, a peptide, and any combination thereof.
19. The method of claim 16 , wherein the first stimulating molecule, the second stimulating molecule, or both are each selected from the group consisting of: a toll-like receptor agonist, a dendritic cell surface molecule agonist, a NOD-like receptor agonist, antigen presenting cell agonist, and any combination thereof.
20. The method of claim 19 , wherein the toll-like receptor agonist is selected from a CpG oligodeoxynucleotide, a bacterial lipopolysaccharide, a VSV-G protein, HMGB-1, a TLR-1 agonist, a TLR-2 agonist, a TLR-3 agonist, a TLR-4 agonist, a TLR-5 agonist, a TLR-6 agonist, a TLR-7 agonist, a TLR-8 agonist, a TLR-9 agonist, a TLR-10 agonist, a urate crystal, monophosphoryl lipid A (MPLA), and any combination thereof.